Catalyst Dossier · compiled by CeliA 🧫

Greenwich LifeSciences, Inc. (GLSI)

Pharmaceutical Preparations · market cap $343M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-13Earningsimp 5/10
2026-12-15 (est.)Phase 3 · GLSI-100imp 9/10

Pipeline

Asset	Phase	Indication
GLSI-100	Phase 3	Breast Cancer
GC1102 50,000 IU	Phase 2	Hepatitis B Infection
CBD	Phase 2	Diabetic Neuropathies
GC3114	Phase 2	Influenza, Human
GC3110A	Phase 3	Influenza
GC3102C	Phase 3	Prophylaxis Against Influenza
Adjuvanted influenza A(H1N1) vaccine	Phase 3	Influenza Infection
GHB16L2	Phase 2	Influenza, Human
Hunterase	Phase 3	Hunter Syndrome
Tetanus and Diphtheria(Td vaccine)	Phase 3	Bacterial Infections
GHB11L1	Phase 2	Influenza, Human
irinotecan	Phase 2	Metastatic Colorectal Cancer
Human immunoglobulin intravenous	Phase 3	Immune Thrombocytopenia
Quadrivalent cell-culture based influenza vaccin	Phase 2	Influenza
GC3110A(Quadrivalent)	Phase 3	Influenza
GC1107	Phase 3	Bacterial Infections
Quadrivalent influenza vaccine	Phase 2	Influenza
GC5107	Phase 3	Immunologic Deficiency Syndromes
Step 1	Phase 2	Influenza
Varicella Vaccine	Phase 3	Healthy Children

Price & technical context

3-month

-1.3%

6-month

-4.4%

12-month

+161.3%

52-wk range

$7.85–$33.56

vs 50-day MA

-1.8%

vs 200-day MA

+20.7%

Realized vol

94.8%

Max drawdown

-55.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for GLSI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.